Methods for treating ocular inflammatory diseases
A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
1. A method of treating blepharitis comprising administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis, said, active ingredient consisting essentially of a glucocorticoid, said ophthalmically acceptable vehicle comprising an aqueous polymer suspension that when mixed with tear-fluid provides a sustained release of said active ingredient, wherein said aqueous polymer suspension comprises a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises
wherein the method does not comprise administration of an antibiotic.
2. The method of claim 1 , wherein the glucocorticoid is selected from the group consisting of hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, and fluorometholone.
3. The method of claim 2 , wherein the glucocorticoid is dexamethasone.
4. The method of claim 1 , wherein the glucocorticoid is present in a range from about 0.05% and to about 0,5% by weight.
5. The method of claim 4 , wherein the glucocorticoid is present in a range from about 0.08% to about 0.52% by weight.
6. The method of claim 1 , wherein the glucocorticoid is present in at about 0.1% by weight.
7. The method of claim 1 , wherein said ophthalmically acceptable vehicle further comprises a preservative.
8. The method of claim 6 , wherein said preservative comprises benzalkonium chloride.
9. The method of claim 8 , wherein said preservative is present in a range from about 0.001 to about 0.005% by weight.